StockNews.com started coverage on shares of Lipocine (NASDAQ:LPCN – Free Report) in a research note issued to investors on Friday morning. The brokerage issued a hold rating on the specialty pharmaceutical company’s stock.
Separately, Alliance Global Partners assumed coverage on Lipocine in a research note on Tuesday, September 24th. They issued a “buy” rating and a $10.00 price target for the company.
Get Our Latest Stock Analysis on LPCN
Lipocine Price Performance
Lipocine (NASDAQ:LPCN – Get Free Report) last released its earnings results on Thursday, November 7th. The specialty pharmaceutical company reported ($0.44) EPS for the quarter. On average, equities analysts expect that Lipocine will post -0.78 EPS for the current year.
Institutional Investors Weigh In On Lipocine
An institutional investor recently bought a new position in Lipocine stock. Dimensional Fund Advisors LP acquired a new stake in Lipocine Inc. (NASDAQ:LPCN – Free Report) during the second quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 11,870 shares of the specialty pharmaceutical company’s stock, valued at approximately $98,000. Dimensional Fund Advisors LP owned about 0.22% of Lipocine as of its most recent filing with the SEC. Hedge funds and other institutional investors own 9.11% of the company’s stock.
About Lipocine
Lipocine Inc, a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate.
See Also
- Five stocks we like better than Lipocine
- The Significance of a Trillion-Dollar Market Cap Goes Beyond a Number
- Earn High Dividends With 2 Top REITs Set to Perform in 2025
- What is the Euro STOXX 50 Index?
- Oilfield Leader SLB: An AI Name You Need to Know
- High Flyers: 3 Natural Gas Stocks for March 2022
- Top ETFs That Beat the Market in 2024 and Could Do It Again
Receive News & Ratings for Lipocine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lipocine and related companies with MarketBeat.com's FREE daily email newsletter.